UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

120 Role of PET scanning in upstaging of small cell lung cancer (SCLC)

Lung cancer (Amsterdam, Netherlands), 2011, Vol.71, p.S41-S42

2011

Volltextzugriff (PDF)

667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer

Annals of oncology, 2023-10, Vol.34, p.S469-S469

2023

Volltextzugriff (PDF)

1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)

Annals of oncology, 2024-09, Vol.35, p.S969-S970

2024

Volltextzugriff (PDF)

627P Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer

Annals of oncology, 2024-09, Vol.35, p.S500-S501

2024

Volltextzugriff (PDF)

1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)

Annals of oncology, 2024-09, Vol.35, p.S977-S978

2024

Volltextzugriff (PDF)

628P Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis

Annals of oncology, 2024-09, Vol.35, p.S501-S502

2024

Volltextzugriff (PDF)

20P Switching to S-1-based adjuvant treatment is feasible in colorectal cancer patients after cardiotoxicity on fluoropyrimidine-based treatment: A retrospective multicentre observational study

Annals of oncology, 2024-06, Vol.35, p.S10-S10

2024

Volltextzugriff (PDF)

1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)

Annals of oncology, 2023-10, Vol.34, p.S968-S969

2023

Volltextzugriff (PDF)

222O Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours

Annals of oncology, 2022-11, Vol.33, p.S1521-S1522

2022

Volltextzugriff (PDF)

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

Annals of oncology, 2022-09, Vol.33, p.S751-S752

2022

Volltextzugriff (PDF)

11P Impact of testicular cancer on socio-economic and sexual health of survivors: A questionnaire-based survey

ESMO open, 2024-03, Vol.9, p.102405, Article 102405

2024

Volltextzugriff (PDF)

668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer

Annals of oncology, 2023-10, Vol.34, p.S470-S470

2023

Volltextzugriff (PDF)

669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

Annals of oncology, 2021-09, Vol.32, p.S694-S694

2021

Volltextzugriff (PDF)

1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial

Annals of oncology, 2022-09, Vol.33, p.S1194-S1195

2022

Volltextzugriff (PDF)

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

Annals of oncology, 2022-09, Vol.33, p.S1162-S1163

2022

Volltextzugriff (PDF)

227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199

Annals of oncology, 2020-11, Vol.31, p.S1330-S1330

2020

Volltextzugriff (PDF)

61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199

Annals of oncology, 2021-09, Vol.32, p.S383-S383

2021

Volltextzugriff (PDF)

Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results

Annals of oncology, 2013-09, Vol.24 (9), p.2462-2463

2013

Volltextzugriff (PDF)

Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period

Breast (Edinburgh), 2024-08, Vol.76, p.103739, Article 103739

2024

Volltextzugriff (PDF)

Axillary nodal burden in primary breast cancer patients with positive pre-operative ultrasound guided fine needle aspiration cytology: Management in the era of ACOSOG Z011

European journal of surgical oncology, 2015-04, Vol.41 (4), p.559-565

2015

Volltextzugriff (PDF)

Observations of core toroidal rotation reversals in Alcator C-Mod ohmic L-mode plasmas

Nuclear fusion, 2011-08, Vol.51 (8), p.83005

2011

Volltextzugriff (PDF)

Impacts of COVID-19 lockdown on private domestic groundwater sample numbers, E. coli presence and E. coli concentration across Ontario, January 2020–March 2021: An interrupted time-series analysis

The Science of the total environment, 2022-03, Vol.814, p.152634-152634, Article 152634

2022

Volltextzugriff (PDF)

Clinical and Survival Outcomes Using Percutaneous Cholecystostomy Tube Alone or Subsequent Interval Cholecystectomy to Treat Acute Cholecystitis

Journal of gastrointestinal surgery, 2020-03, Vol.24 (3), p.627-632

2020

Volltextzugriff (PDF)

Equipping for risk: Lessons learnt from the UK shale-gas experience on assessing environmental risks for the future geoenergy use of the deep subsurface

The Science of the total environment, 2024-04, Vol.921, p.171036-171036, Article 171036

2024

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(57)
Tagungsberichte
(1)

Sprache

Englisch
(58)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(15)
Humans
(11)
Surgery
(11)
Female
(6)
Hematology, Oncology And Palliative Medicine
(6)
Middle Aged
(5)
Oncology
(5)
Physical Sciences
(5)
Engineering
(4)
Science & Technology - Other Topics
(4)
Technology
(4)
Adult
(3)
Energy & Fuels
(3)
Engineering, Chemical
(3)
Engineering, Environmental
(3)
Green & Sustainable Science & Technology
(3)
Male
(3)
Retrospective Studies
(3)
Aged
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

120 Role of PET scanning in upstaging of small cell lung cancer (SCLC)

667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer

1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)

627P Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer

1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)

628P Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis

LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

20P Switching to S-1-based adjuvant treatment is feasible in colorectal cancer patients after cardiotoxicity on fluoropyrimidine-based treatment: A retrospective multicentre observational study

1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)

222O Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up

11P Impact of testicular cancer on socio-economic and sexual health of survivors: A questionnaire-based survey

668P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer

669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199

61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199

Role of second-line chemotherapy in advanced pancreatic cancer and its influence on phase II/III study results

Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period

Axillary nodal burden in primary breast cancer patients with positive pre-operative ultrasound guided fine needle aspiration cytology: Management in the era of ACOSOG Z011

Observations of core toroidal rotation reversals in Alcator C-Mod ohmic L-mode plasmas

Impacts of COVID-19 lockdown on private domestic groundwater sample numbers, E. coli presence and E. coli concentration across Ontario, January 2020–March 2021: An interrupted time-series analysis

Clinical and Survival Outcomes Using Percutaneous Cholecystostomy Tube Alone or Subsequent Interval Cholecystectomy to Treat Acute Cholecystitis

Equipping for risk: Lessons learnt from the UK shale-gas experience on assessing environmental risks for the future geoenergy use of the deep subsurface

Suchergebnisse filtern